Abstracts tagged "Amyloidosis"

Abstract Number: 747 • 2012 ACR/ARHP Annual Meeting
Familial Mediterranean Fever: Inhibition of IL-6 Signalling As a New Therapeutic Option in a Frequent Autoinflammatory Syndrome.
Nicola Stein¹, Matthias Witt², Michael Baeuerle³, Fabian Proft¹, Hendrik Schulze-Koops⁴ and Mathias Gruenke¹, ¹Rheumaeinheit, Medizinische Klinik und Poliklinik IV, Klinikum der Universität München, Munich, Germany, ²Division of Rheumatology and Clinical Immunology, University of Munich, Munich, Germany, ³Division of Rheumatology, Klinikum Nürnberg, Nuernberg, Germany, ⁴University of Munich, Munich, Germany
Background/Purpose: Familial Mediterranean Fever (FMF) is the most prevalent episodic fever syndrome with more than 100.000 affected individuals worldwide. Colchicine is the established first-line therapy…
Abstract Number: 194 • 2012 ACR/ARHP Annual Meeting
LONG-TERM Efficacy of Tocilizumab in A Patient with Amyloidosis and Interstitial Pneumonia Secondary to Multicentric Castleman’s Disease (MCD)
Michihito Katayama¹, Soichiro Tsuji¹, Satoshi Teshigawara¹, Eriko Kudo-Tanaka¹, Maiko Yoshimura¹, Akane Watanabe¹, Akiko Yura², Yoshinori Harada³, Yoshinori Katada³, Jun Hashimoto¹, Masato Matsushita⁴, Yukihiko Saeki⁵ and Shiro Ohshima⁵, ¹Dept of Rheumatology, Osaka-Minami Medical Center, Kawachinagano City, Japan, ²Dept of Allergology, Allergology,Osaka-Minami Medical Center, Kawachinagano City, Japan, ³Dept of Allergology, Kawachinagano City, Japan, ⁴Rheumatology, Osaka Minami Medical Center, Osaka, Japan, ⁵Dept of Clinical Research, Osaka-Minami Medical Center, Kawachinagano City, Japan
Background/Purpose: Castleman’s disease is a benign lymphoproliferative disorder characterized histologically by follicular hyperplasia and capillary proliferation with endothelial hyperplasia. In addition, overproduction of Interleukin-6 (IL-6)…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].